Recently, the practice of paying kickbacks to pharmacists who ordered VEEV electronic cigarettes by FirMo International has sparked strong opposition and has been forced to stop.
In Australia, approved patients are allowed to use nicotine e-cigarettes. Pharma international pays kickbacks to pharmacists who order VEEV e-cigarettes. Pharmacists receive $5 AUD (approximately ￥23.16) every time they prescribe VEEV to a patient, and will receive $10 AUD (approximately ￥46.33) for introducing a new patient to the device. They will also receive $5 AUD for referring a patient to a doctor to obtain a VEEV prescription.
Australian health experts have expressed shock at the actions of Philip Morris International. The Pharmaceutical Society of Australia has condemned the multinational tobacco company's practice of offering kickbacks to pharmacists, calling it a blatant disregard of their professional ethics.
This article contains excerpts or reprints from third-party sources. The copyright belongs to the original media and authors. If there is any infringement, please contact us for removal. Any units or individuals wishing to reproduce must contact the author, please do not reproduce directly.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
